| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
214,290,000 |
| Market
Cap: |
36.13(M) |
| Last
Volume: |
2,552,505 |
Avg
Vol: |
2,452,798 |
| 52
Week Range: |
$0.0447 - $0.65 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alaunos Therapeutics is an oncology-focused cell therapy company developing adoptive T-cell receptor (TCR) therapies, designed to treat various solid tumor types in cancer patient. Co. is utilizing its cancer mutation hotspot TCR library and its proprietary, non-viral Sleeping Beauty genetic engineering technology to design and manufacture patient-specific cell therapies that target neoantigens arising from tumor-related mutations in main oncogenic genes, including KRAS, TP53 and EGFR. Co. evaluates TCRs reactive to mutated KRAS, TP53 and EGFR from its TCR library for the investigational treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian and bile duct cancers.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
2,000,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,300,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
68,014 |
68,014 |
| Total Sell Value |
$0 |
$0 |
$9,542 |
$9,542 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vieser Jaime |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,167 |
605,321 |
|
- |
|
| Postma Robert W |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
1,181,362 |
|
- |
|
| Bowden Christopher |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,167 |
4,167 |
|
- |
|
| Weis Holger |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
4,167 |
70,167 |
|
- |
|
| Huang James |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
8,333 |
8,333 |
|
- |
|
| Thistle Mary |
Director |
– • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Hadfield Robert |
Chief Legal Officer and Sec. |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
43,500 |
176,819 |
|
- |
|
| Buck Jill |
EVP, GM Gene Therapy |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
31,500 |
231,016 |
|
- |
|
| De Groot Eleanor |
EVP, GM Cell Therapy |
• – – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
50,825 |
257,238 |
|
- |
|
| Hagen Heidi |
Interim CEO |
• • – |
2021-03-04 |
4 |
A |
$0.00 |
$0 |
D/D |
90,000 |
122,119 |
|
- |
|
| Postma Robert W |
Director |
– • – |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
4,199,082 |
|
-47% |
|
| Postma Robert W |
Director |
– • – |
2021-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,178,862 |
|
-47% |
|
| Buck Jill |
EVP, GM Gene Therapy |
• – – |
2021-01-08 |
4 |
AS |
$3.12 |
$87,029 |
D/D |
(27,894) |
199,516 |
|
-3% |
|
| Lafond Kevin G |
SVP, Treasurer & CAO |
• – – |
2021-01-08 |
4 |
AS |
$3.09 |
$55,682 |
D/D |
(18,020) |
63,965 |
|
-3% |
|
| Hadfield Robert |
General Counsel and Secretary |
• – – |
2021-01-08 |
4 |
AS |
$3.12 |
$82,680 |
D/D |
(26,500) |
133,319 |
|
-3% |
|
| Cooper Laurence James Neil |
President and CEO |
• • – |
2021-01-04 |
4 |
AS |
$2.71 |
$286,428 |
D/D |
(105,693) |
1,799,280 |
|
7% |
|
| De Groot Eleanor |
EVP, GM Cell Therapy |
• – – |
2021-01-04 |
4 |
AS |
$2.72 |
$58,806 |
D/D |
(21,620) |
206,413 |
|
7% |
|
| Vieser Jaime |
Director |
– • – |
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
325,000 |
|
24% |
|
| Vieser Jaime |
Director |
– • – |
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
601,154 |
|
24% |
|
| Weis Holger |
Director |
– • – |
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
21,440 |
|
24% |
|
| Weis Holger |
Director |
– • – |
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
66,000 |
|
24% |
|
| Shukla Sath |
EVP, Chief Financial Officer |
• – – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
80,500 |
80,500 |
|
- |
|
| Buck Jill |
EVP, GM Gene Therapy |
• – – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
53,700 |
227,410 |
|
- |
|
| Mauney David M Md |
President |
• – – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
80,500 |
275,778 |
|
- |
|
| Lafond Kevin G |
SVP, Treasurer & CAO |
• – – |
2020-01-29 |
4 |
A |
$0.00 |
$0 |
D/D |
18,000 |
81,985 |
|
- |
|
308 Records found
|
|
Page 2 of 13 |
|
|
